| Literature DB >> 35013007 |
Do Hyeon Lee1, Hyoung Joo Kim1, Chan Woo Cho1, Sung Su Yun1, Dong-Shik Lee1.
Abstract
Backgrounds/Aims: Pancreaticoduodenectomy (PD) is a standard surgical procedure for patients with periampullary cancer. During the follow-up period after PD, recurrence can be observed in various places with different prognosis. The aim of this study was to clarify the pattern of recurrence and factors affecting the survival of patients with periampullary cancer.Entities:
Keywords: Bile duct cancer; Metastasis; Pancreaticoduodenectomy; Recurrence
Year: 2022 PMID: 35013007 PMCID: PMC9136428 DOI: 10.14701/ahbps.21-129
Source DB: PubMed Journal: Ann Hepatobiliary Pancreat Surg ISSN: 2508-5859
Demographic and clinicopathologic factors of patients who underwent pancreaticoduodenectomy as primary treatment for periampullary cancer
| Characteristic | No recurrence (n = 42) | Isolated LR (n = 14) | DM (n = 32 ) | |
|---|---|---|---|---|
| Mean age (yr) | 60.5 ± 8.6 | 62.2 ± 7.7 | 61.8 ± 10.1 | 0.162 |
| Sex | 0.642 | |||
| Male | 26 (61.9) | 10 (71.4) | 18 (56.3) | |
| Female | 16 (38.1) | 4 (28.6) | 14 (43.8) | |
| Preoperative CEA (ng/mL) | 2.68 (0.01–17) | 1.7 (0.01–5) | 2.7 (0.01–26) | 0.474 |
| Preoperative CA19-9 (U/mL) | 26.4 (1.92–100,000) | 25.6 (0–217) | 62.1 (0–1,000) | 0.023 |
| Preoperative biliary drainage | 31 (73.8) | 13 (92.9) | 26 (81.3) | 0.472 |
| Cancer type | 0.046 | |||
| Distal CBD cancer | 18 (42.9) | 7 (50.0) | 23 (71.9) | |
| AoV cancer | 24 (57.1) | 7 (50.0) | 9 (28.1) | |
| Adjuvant chemotherapy | 15 (35.7) | 7 (50.0) | 21 (65.7) | 0.02 |
| Differentiation | 0.045 | |||
| Well | 10 (23.8) | 2 (14.3) | 2 (6.3) | |
| Moderated | 25 (59.5) | 9 (64.3) | 21 (65.6) | |
| Poor | 7 (16.7) | 3 (21.4) | 9 (28.1) | |
| T stage[ | 0.016 | |||
| 1 | 18 (42.9) | 3 (21.4) | 7 (21.9) | |
| 2 | 11 (26.2) | 1 (7.1) | 4 (12.5) | |
| 3 | 8 (19.0) | 6 (42.9) | 17(53.1) | |
| 4 | 5 (11.9) | 4 (28.6) | 4 (12.5) | |
| N stage[ | 0.001[ | |||
| 0 | 31 (73.8) | 9 (64.3) | 10 (31.3) | |
| 1 | 11 (26.2) | 5 (35.7) | 22 (68.8) | |
| Lymphovascular invasion | 21 (50.0) | 10 (71.4) | 27 (84.4) | 0.008 |
| Perineural invasion | 10 (23.8) | 7 (50.0) | 26 (81.3) | < 0.001 |
Values are presented as mean ± standard deviation, number (%), or median (range).
LR, local recurrence; DM, distant metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CBD, common bile duct; AoV, ampulla of Vater.
*Statistically significance (p < 0.05).
a)AJCC 7th edition. b)Fisher-exact test.
Site of recurrence at the first time of recognition
| Recurrence pattern | Distal CBD cancer | AoV cancer |
|---|---|---|
| Locoregional recurrence | 15 | 5 |
| Around SMA | 3 | 5 |
| Around celiac axis | 2 | 0 |
| Portocaval area (near hilar lesion) | 13 | 4 |
| Distant metastasis | 29 | 14 |
| Liver | 15 | 7 |
| Paraaortic | 12 | 9 |
| Peritoneum | 6 | 4 |
| Remained pancreas | 1 | 1 |
| Others | 7 | 2 |
Values are presented as number only.
CBD, common bile duct; AoV, ampulla of Vater; SMA, superior mesenteric artery.
Univariate and multivariate analyses of risk factors associated with isolated local recurrence
| Risk factor | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| HR | 95% CI | HR | 95% CI | ||||
| Age, ≥ 65 years | 1.103 | 0.324–3.754 | 0.875 | ||||
| Sex, female | 0.650 | 0.174–2.424 | 0.749 | ||||
| Preoperative biliary drainage | 4.613 | 0.539–39.487 | 0.258 | ||||
| Cancer type, dCBD vs. AoV | 0.750 | 0.223–2.522 | 0.759 | ||||
| T stage, T3/4 vs. T1/2 | 5.577 | 1.473–21.115 | 0.012 | 5.577 | 1.473–21.115 | 0.011 | |
| Lymph node metastasis | 1.566 | 0.430–5.697 | 0.511 | ||||
| Histologic difference | |||||||
| Poor vs. well, moderate | 1.364 | 0.30–6.189 | 0.698 | ||||
| Lymphovascular invasion | 1.750 | 0.725–4.226 | 0.220 | ||||
| Perineural invasion | 1.524 | 0.879–2.642 | 0.094 | ||||
| Adjuvant chemotherapy | 0.714 | 0.368–1.386 | 0.363 | ||||
HR, hazards ratio; CI, confidence interval; dCBD, distal common bile duct; AoV, ampulla of Vater.
Univariate and multivariate analyses of risk factors associated with distant metastasis
| Risk factor | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| HR | 95% CI | HR | 95% CI | ||||
| Age, ≥ 65 years | 1.298 | 0.513–3.283 | 0.640 | ||||
| Sex, female | 0.871 | 0.502–1.510 | 0.641 | ||||
| Preoperative biliary drainage | 1.538 | 0.500–4.727 | 0.580 | ||||
| Cancer type, dCBD vs. AoV | 2.032 | 1.101–3.749 | 0.018 | 2.470 | 0.279–21.867 | 0.417 | |
| T stage, T3/4 vs. T1/2 | 4.259 | 1.599–11.346 | 0.005 | 1.211 | 0.313–4.689 | 0.782 | |
| Lymph node metastasis | 6.2 | 2.245–17.122 | < 0.001 | 0.322 | 0.088–1.175 | 0.086 | |
| Histologic difference | |||||||
| Poor vs. well, moderate | 1.957 | 0.639–5.991 | 0.266 | ||||
| Lymphovascular invasion | 3.2 | 1.354–7.563 | 0.003 | 3.662 | 0.891–15.043 | 0.072 | |
| Perineural invasion | 4.063 | 1.937–8.524 | < 0.001 | 0.267 | 0.081–0.884 | < 0.001 | |
| Adjuvant chemotherapy | 3.960 | 1.489–10.534 | 0.009 | 3.405 | 0.797–14.549 | 0.098 | |
HR, hazards ratio; CI, confidence interval; AoV, ampulla of Vater; dCBD, distal common bile duct.
Fig. 1Overall survival according to recurrence pattern.
Fig. 2Overall survival according to cancer type. dCBD, distal common bile duct; AoV, ampulla of Vater.